|
David Castaldi earned his B.B.A. from the University of Notre Dame in 1962 and graduated from Harvard Business School in 1966. He co-founded Cadent Medical Corporation in 1996 and was appointed CEO in 1998. From 1995 to 1998, Mr. Castaldi served as Chairman, CEO, and Director of Biolink Corporation. Mr. Castaldi is also the former founder, President, CEO, and Director of a publicly held tissue engineering company, BioSurface Technology, Inc., that developed and marketed the world’s first tissue-engineered human tissue product and the first tissue-engineered orthopaedic product brought to market. He sold BioSurface Technology, Inc., to Genzyme Corp. In addition, he has been CEO of two other start-up medical device companies, and for ten years he was President of Hyland Therapeutics, a division of Baxter International. He currently serves on the Board of Directors of two Nasdaq-listed life science companies and two privately-held companies. | 